A261780 Stock Overview
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products targeting infectious and chronic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CHA Vaccine Research Institute Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,660.00 |
| 52 Week High | ₩7,660.00 |
| 52 Week Low | ₩3,715.00 |
| Beta | 0.78 |
| 11 Month Change | 0.98% |
| 3 Month Change | -4.02% |
| 1 Year Change | -10.04% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.15% |
Recent News & Updates
Shareholder Returns
| A261780 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 16.1% | 3.1% | -3.1% |
| 1Y | -10.0% | 26.7% | -2.4% |
Return vs Industry: A261780 underperformed the KR Biotechs industry which returned 26.7% over the past year.
Return vs Market: A261780 underperformed the KR Market which returned -2.4% over the past year.
Price Volatility
| A261780 volatility | |
|---|---|
| A261780 Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A261780 has not had significant price volatility in the past 3 months.
Volatility Over Time: A261780's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Jungsun Yum | www.chavaccine.com |
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products targeting infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster. The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer vaccine.
CHA Vaccine Research Institute Fundamentals Summary
| A261780 fundamental statistics | |
|---|---|
| Market cap | ₩124.57b |
| Earnings (TTM) | -₩1.47b |
| Revenue (TTM) | ₩542.91m |
229.4x
P/S Ratio-84.6x
P/E RatioIs A261780 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A261780 income statement (TTM) | |
|---|---|
| Revenue | ₩542.91m |
| Cost of Revenue | ₩45.11m |
| Gross Profit | ₩497.80m |
| Other Expenses | ₩1.97b |
| Earnings | -₩1.47b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -55.06 |
| Gross Margin | 91.69% |
| Net Profit Margin | -271.09% |
| Debt/Equity Ratio | 12.3% |
How did A261780 perform over the long term?
See historical performance and comparison